drugset
drugset / Trial / NCT07080385

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

NCT07080385 ↗

Phase 2/3 Recruiting 28 enrolled Calcilytix Therapeutics, Inc., a BridgeBio company
NaSequentialOpen-labelTreatment

Summary

The overall objective of this study is to evaluate the pharmacokinetics (PK), efficacy, and safety of encaleret in pediatric participants from birth to 17 years of age with ADH1.

Timeline

Start
2026-01-30
Primary completion
2028-12
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Encaleret Small molecule — Oral

Indications

autosomal dominant hypocalcemia 1